Vol 8, Supplement 2 (March 2019): Translational Cancer Research

Editorial

Third line scenario in advanced non-small cell lung cancer: is the anti-angiogenetic strategy the only actor up to now?
Caterina Mecca, Valentina Bertaglia, Silvia Novello
Postmastectomy radiation therapy in women with T1–T2 tumors and 1 to 3 positive lymph nodes: analysis of the breast international group 02-98 trial
Fabiana Gregucci, Maria Carmen De Santis, Laura Lozza, Alba Fiorentino
Anti-GD2 CAR T cells could prove transformative for H3-K27M+ diffuse midline gliomas
Koichi Furukawa, Yuhsuke Ohmi, Keiko Furukawa
The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study
Giandomenico Roviello, Daniele Generali, Navid Sobhani
Value of magnetic resonance imaging in predicting BRAF mutation in craniopharyngiomas
Mario Giordano, Ismail Zaed
A new paradox for pCR in BRCA mutation carriers
Konstantinos Rounis, Dimitrios Mavroudis
Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?
Andrea Bianco, Susan F. M. Campbell
CircNT5E/miR-422a: a new circRNA-based ceRNA network in glioblastoma
Deborah Morena, Francesca Picca, Riccardo Taulli
Whether adjuvant radiotherapy is desired for postmastectomy patients with T1–T2 tumors and 1–3 positive axillary lymph nodes who received modern systemic therapy?
Shih-Fan Lai, Chiun-Sheng Huang, Sung-Hsin Kuo
Proton beam radiosurgery: early clinical results
Janet Leon, Jennifer Peterson, Austin Hadley, Laura Vallow, Daniel M. Trifiletti
Impact of breast surgery in de novo stage IV breast cancer
Tadahiko Shien
Evolving development of multi-parametric normal tissue complication probability model for liver radiotherapy
Chiao-Ling Tsai, Jason Chia-Hsien Cheng
Development and validation of a polygenic hazard score for aggressive prostate cancer identification
Nihal E. Mohamed, Ashutosh K. Tewari, Kamlesh K. Yadav
Circular RNA as a prospective molecular tool for the study of neuroprotection in cerebral ischemia
Svetlana A. Limborska, Ivan B. Filippenkov
The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape
Vadim S. Koshkin, Arnab Basu, Petros Grivas
ARID1A: guardian of normal pancreatic ducts
Karla J. Castellanos, Paul J. Grippo
Twist1 activated circRNA-10720 is a new player in hepatocellular carcinoma metastasis
Alfons Navarro
Prospects for cost-effective lung cancer screening using risk calculators
Marianne Weber, Annette McWilliams, Karen Canfell
Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
Danilo Rocco, Luigi Della Gravara, Umberto Malapelle, Giancarlo Troncone, Cesare Gridelli
Metastasis suppression and enhancement of anti-tumour immunity by targeting the FSTL1-DIP2A axis
Gopinath M. Sundaram, Shan Quah, Prabha Sampath
Editorial on the integrated multidisciplinary algorithm for the management of spinal metastases
Wen Jie Choy, Kevin Phan, Ralph J. Mobbs
The time has come to pull renal cancer’s sweet tooth
Adam Kinnaird, Evangelos D. Michelakis
Bevacizumab in recurrent glioblastoma
Nina L. Martinez, Jon Glass, Wenyin Shi
The updated AJCC/TNM staging system (8th edition) for oral tongue cancer
Kyubo Kim, Dong Jin Lee
(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas
Leland G. Richardson, Bryan D. Choi, William T. Curry
Oligometastatic prostate cancer: is it worth targeting the tip of the iceberg?
Stéphane Supiot, Caroline Rousseau
Neoadjuvant cisplatin-based chemotherapy in “primary” and “secondary” muscle-invasive bladder cancer—is it a surrogate for molecular subtypes?
Tibor Szarvas, Csilla Olah, Henning Reis
Role of pelvic lymph node dissection in bladder cancer: is it better to do more?
Anthony Dat, Shomik Sengupta
Squaring the circle: sponging microRNAs in gastric cancer
Steven G. Gray
Treatment intensity in locoregionally advanced head and neck cancer: recent investigation leads to new questions
James A. Bonner, Drexell H. Boggs
Circular RNA YAP1: a new player in gastric cancer
Lorena Verduci, Giovanni Blandino
Multimodal action of ONECUT2 in driving neuroendocrine prostate cancer
Salma Kaochar, Nicholas Mitsiades